Pacira BioSciences, Inc.PCRXNASDAQ
Loading
Year-over-year operating income growth rate
Percentile
P36
Within normal range
vs 5Y Ago
-7.6x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -49.84% |
| Q3 2025 | -25.14% |
| Q2 2025 | 327.09% |
| Q1 2025 | -91.94% |
| Q4 2024 | 117.71% |
| Q3 2024 | -594.08% |
| Q2 2024 | 113.75% |
| Q1 2024 | -60.17% |
| Q4 2023 | 87.17% |
| Q3 2023 | -55.56% |
| Q2 2023 | 1390.10% |
| Q1 2023 | 68.76% |
| Q4 2022 | -146.47% |
| Q3 2022 | -31.84% |
| Q2 2022 | 79.58% |
| Q1 2022 | 313.04% |
| Q4 2021 | -86.60% |
| Q3 2021 | -9.79% |
| Q2 2021 | 79.26% |
| Q1 2021 | 3.49% |
| Q4 2020 | 6.59% |
| Q3 2020 | 346.54% |
| Q2 2020 | -141.81% |
| Q1 2020 | 897.32% |
| Q4 2019 | -28.97% |
| Q3 2019 | -54.26% |
| Q2 2019 | 388.88% |
| Q1 2019 | -91.20% |
| Q4 2018 | 202.92% |
| Q3 2018 | -38.11% |
| Q2 2018 | 194.29% |
| Q1 2018 | -181.96% |
| Q4 2017 | 336.95% |
| Q3 2017 | 77.36% |
| Q2 2017 | -12.31% |
| Q1 2017 | -470.91% |
| Q4 2016 | 88.21% |
| Q3 2016 | -223.79% |
| Q2 2016 | -185.89% |
| Q1 2016 | -177.24% |